Skip to content
AwardedPOLGoodsPLN 666,667

Zakup leków w ramach programów lekowych - leczenie przewlekłego WZW typu B i C oraz profilaktyki wznowy przewlekłych zapaleń WZW typu B u chorych po przeszczepach narządowych i leczonych onkologicznie

Published
Published 15 May 2026
Deadline
Closed 19 June 2026

Overview

Szpital Miejski św. Jana Pawła II w Elblągu procured pharmaceutical products for treating chronic hepatitis B and C and preventing relapse of chronic hepatitis B inflammation in patients after organ transplants and undergoing oncological treatment under drug programs. The contract was awarded on 29 June 2026 to Abbvie sp. zo.o., Asclepios S.A., Farmacol Logistyka Sp. z o.o., and Urtica Sp. z o.o. for a total value of 1,538,326.43 PLN.

Key details

Country
POL
Status
Awarded
Category
Goods
Estimated value
PLN 666,667
Procedure
Open
Published
15 May 2026
Deadline
Closed
Classification (CPV)
Pharmaceutical products

Award outcome

Awarded value
PLN 1,538,326
Award date
29 June 2026
Contract period
— → 24 June 2027
Winners
  • Abbvie sp. zo.o.
  • Asclepios S.A.
  • Farmacol Logistyka Sp. z o.o.
  • Urtica Sp. z o.o.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    14 July 2026

  2. Contract Notice

    15 June 2026

  3. Contract Notice

    14 May 2026

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Zakup leków w ramach programów lekowych - leczenie przewlekłego WZW typu B i C oraz profilaktyki wznowy przewlekłych zapaleń WZW typu B u chorych po przeszczepach narządowych i leczonych onkologicznie — won by Abbvie sp. zo.o. +3 — Skim